

***eTable 1 Electrophysiological and MRI Outcomes in MS and NMOSD Clinical Trials with less than 20 participants***

<b>NCT03062579 (13)</b> 10 (active NMOSD)	Tocilizumab	Secondary (changes in ffVEP latency) - ongoing	<b>T2 lesion activity:</b> Secondary outcome – number of lesions
<b>NCT03605238 (3)</b> Active AQP4-IgG positive NMOSD	Corticosteroids & tanCART19/20	Secondary (changes in flash VEP latency) - withdrawn	-
<b>NCT01883661 (14)</b> 15 (late MS)	Autologous Bone Marrow Derived Mono Nuclear Stem Cell (MNCs)	Secondary (changes in ffVEP) - unknown	-
<b>NCT01364246 (16)</b> 20 (MS, NMOSD)	Human umbilical cord mesenchymal stem cells transplantation	Secondary (change in ffVEP P100 latency) - unknown	<b>T2 lesion activity:</b> change in lesion load at 12 months
<b>NCT02760056 (MST3K)<sup>36</sup></b> 15 (MS)	Liothyronine sodium (25 mcg, 37.5mcg, 50 mcg, 75 mcg ) vs. placebo	Secondary (Reliability of ffVEP testing (ICC)) ICC(VEP17'): 0.836 ICC(VEP34'): 0.860 Reduced P100 latency for VEP 17' (1.9 ms/eye) and 34' (0.4 ms/eye)	
<b>NCT01647880 (MOVING)<sup>147</sup></b> 9 (RRMS, acute ON)	Fingolimod (0.5mg/d) vs. interferon-beta-1b	Primary (mfVEP latency) Secondary (ffVEP latency) Larger p100 latency reduction in fingolimod (15.7ms) than interferon-beta-1b (8.2ms, p<0.001)	<b>T2 lesion activity:</b> New and/or enhancing T2 lesions – no difference reported.
<b>NCT03774407 (27)</b> 20 (female, RRMS)	Estriol vaginal cream	Secondary (change in ffVEP P100 latency) - ongoing	<b>MTR:</b> Secondary: whole brain MTR

## E-References

<sup>e1</sup> Knier B, Schmidt P, Aly L, et al. Retinal inner nuclear layer volume reflects response to immunotherapy in multiple sclerosis. *Brain* 2016; 139: 2855-2863. 2016/09/02. DOI: 10.1093/brain/aww219.

<sup>e2</sup> Green AJ, McQuaid S, Hauser SL, et al. Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. *Brain* 2010; 133: 1591-1601. 2010/04/23. DOI: 10.1093/brain/awq080.

<sup>e3</sup> Saidha S, Sotirchos ES, Ibrahim MA, et al. Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. *Lancet Neurol* 2012; 11: 963-972. DOI: 10.1016/S1474-4422(12)70213-2.

- <sup>e4</sup> Sotirchos ES, Saidha S, Byraiah G, et al. In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. *Neurology* 2013; 80: 1406-1414. 2013/03/22. DOI: 10.1212/WNL.0b013e31828c2f7a.
- <sup>e5</sup> Gelfand JM, Nolan R, Schwartz DM, et al. Microcystic macular oedema in multiple sclerosis is associated with disease severity. *Brain* 2012; 135: 1786-1793. DOI: 10.1093/brain/aws098.
- <sup>e6</sup> Ramanathan S, Prelog K, Barnes EH, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. *Mult Scler* 2016; 22: 470-482. 2015/07/15. DOI: 10.1177/1352458515593406.
- <sup>e7</sup> Balk LJ, Steenwijk MD, Tewarie P, et al. Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2015; 86: 419-424. 2014/06/29. DOI: 10.1136/jnnp-2014-308189.
- <sup>e8</sup> Fischl B, Sereno MI and Dale AM. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. *Neuroimage* 1999; 9: 195-207. 1999/02/05. DOI: 10.1006/nimg.1998.0396.
- <sup>e9</sup> Jenkins TM, Toosy AT, Ciccarelli O, et al. Neuroplasticity predicts outcome of optic neuritis independent of tissue damage. *Ann Neurol* 2010; 67: 99-113. 2010/02/27. DOI: 10.1002/ana.21823.
- <sup>e10</sup> The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. *Arch Ophthalmol* 1991; 109: 1673-1678. 1991/12/01. DOI: 10.1001/archoph.1991.01080120057025.
- <sup>e11</sup> Talman, LS, Bisker, ER, Sackel, DJ. Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. *Ann Neurol* 2010; 67(6): 749-760.
- <sup>e12</sup> Balcer LJ, Raynowska J, Nolan R, et al. Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. *Mult Scler* 2017; 23: 734-747. 2017/02/17. DOI: 10.1177/1352458517690822.
- <sup>e13</sup> Richman J, Spaeth GL and Wirostko B. Contrast sensitivity basics and a critique of currently available tests. *Journal of cataract and refractive surgery* 2013; 39: 1100-1106. 2013/05/28. DOI: 10.1016/j.jcrs.2013.05.001.
- <sup>e14</sup> Balcer LJ, Raynowska J, Nolan R, et al. Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. *Multiple sclerosis (Houndmills, Basingstoke, England)* 2017; 23: 734-747. 2017/02/17. DOI: 10.1177/1352458517690822.
- <sup>e15</sup> Yeung WK, Dawes P, Pye A, et al. eHealth tools for the self-testing of visual acuity: a scoping review. *NPJ Digit Med* 2019; 2: 82. 2019/08/28. DOI: 10.1038/s41746-019-0154-5.
- <sup>e15</sup> Campo Dall'Orto G, Facchin A, Bellatorre A, et al. Measurement of visual acuity with a digital eye chart: optotypes, presentation modalities and repeatability. *J Optom* 2020 2020/11/04. DOI: 10.1016/j.optom.2020.08.007.
- <sup>e16</sup> Falardeau J, Fryman A, Wanchu R, et al. Oral lipoic acid as a treatment for acute optic neuritis: a blinded, placebo controlled randomized trial. *Mult Scler J Exp Transl Clin* 2019; 5: 2055217319850193. 2019/06/18. DOI: 10.1177/2055217319850193.
- <sup>e17</sup> Esfahani MR, Harandi ZA, Movasat M, et al. Memantine for axonal loss of optic neuritis. *Graefes Arch Clin Exp Ophthalmol* 2012; 250: 863-869. 2011/12/17. DOI: 10.1007/s00417-011-1894-3.
- <sup>e18</sup> Suhs KW, Hein K, Sattler MB, et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. *Ann Neurol* 2012; 72: 199-210. 2012/08/29. DOI: 10.1002/ana.23573.
- <sup>e19</sup> Green AJ. Visual Evoked Potentials, Electroretinography, and Other Diagnostic Approaches to the Visual System. In: Aminoff M (ed) *Electrodiagnosis in Clinical Neurology* Elsevier, 2012, pp.477-503.

- e20 Vabanesi M, Pisa M, Guerrieri S, et al. In vivo structural and functional assessment of optic nerve damage in neuromyelitis optica spectrum disorders and multiple sclerosis. *Sci Rep* 2019; 9: 10371. 2019/07/19. DOI: 10.1038/s41598-019-46251-3.
- e21 Fuhr P, Borggreffe-Chappuis A, Schindler C, et al. Visual and motor evoked potentials in the course of multiple sclerosis. *Brain* 2001; 124: 2162-2168. 2001/10/24. DOI: 10.1093/brain/124.11.2162.
- e22 Schlaeger R, D'Souza M, Schindler C, et al. Combined evoked potentials as markers and predictors of disability in early multiple sclerosis. *Clin Neurophysiol* 2012; 123: 406-410. 2011/07/23. DOI: 10.1016/j.clinph.2011.06.021.
- e23 Chen JJ, Flanagan EP, Jitprapaikulsan J, López-Chiriboga ASS, Fryer JP, Leavitt JA, et al. Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. *Am J Ophthalmol*. 2018 Nov;195:8–15.
- e24 Schinzel J, Zimmermann H, Paul F, et al. Relations of low contrast visual acuity, quality of life and multiple sclerosis functional composite: a cross-sectional analysis. *BMC Neurol* 2014; 14: 31. 2014/02/22. DOI: 10.1186/1471-2377-14-31.
- e25 Persson HE and Wanger P. Pattern-reversal electroretinograms and visual evoked cortical potentials in multiple sclerosis. *Br J Ophthalmol* 1984; 68: 760-764. 1984/10/01. DOI: 10.1136/bjo.68.10.760.
- e26 Janaky M, Janossy A, Horvath G, et al. VEP and PERG in patients with multiple sclerosis, with and without a history of optic neuritis. *Doc Ophthalmol* 2017; 134: 185-193. 2017/04/20. DOI: 10.1007/s10633-017-9589-7.
- e27 Klistorner A, Arvind H, Garrick R, et al. Interrelationship of optical coherence tomography and multifocal visual-evoked potentials after optic neuritis. *Invest Ophthalmol Vis Sci* 2010; 51: 2770-2777. 2010/01/01. DOI: 10.1167/iovs.09-4577.
- e28 Pihl-Jensen G, Schmidt MF and Frederiksen JL. Multifocal visual evoked potentials in optic neuritis and multiple sclerosis: A review. *Clin Neurophysiol* 2017; 128: 1234-1245. 2017/05/23. DOI: 10.1016/j.clinph.2017.03.047.
- e29 Klistorner A, Arvind H, Nguyen T, et al. Multifocal VEP and OCT in optic neuritis: a topographical study of the structure-function relationship. *Doc Ophthalmol* 2009; 118: 129-137. 2008/09/10. DOI: 10.1007/s10633-008-9147-4.
- e30 Schnurman ZS, Frohman TC, Beh SC, et al. Retinal architecture and mfERG: Optic nerve head component response characteristics in MS. *Neurology* 2014; 82: 1888-1896. 2014/05/03. DOI: 10.1212/WNL.0000000000000447.
- e31 Filgueiras TG, Oyamada MK, Preti RC, et al. Outer Retinal Dysfunction on Multifocal Electroretinography May Help Differentiating Multiple Sclerosis From Neuromyelitis Optica Spectrum Disorder. *Front Neurol* 2019; 10: 928. 2019/09/12. DOI: 10.3389/fneur.2019.00928.
- e32 Pihl-Jensen G, Ivanov I, Hinze D, et al. Sensitive Assessment of Acute Optic Neuritis by a New, Digital Flicker Test. *Ophthalmic Res* 2020; 63: 332-340. 2019/10/28. DOI: 10.1159/000503304.
- e33 Ayadi N, Dorr J, Motamedi S, et al. Temporal visual resolution and disease severity in MS. *Neurol Neuroimmunol Neuroinflamm* 2018; 5: e492. 2018/09/04. DOI: 10.1212/NXI.0000000000000492.
- e34 Raz N, Hallak M, Ben-Hur T, et al. Dynamic visual tests to identify and quantify visual damage and repair following demyelination in optic neuritis patients. *J Vis Exp* 2014 2014/05/07. DOI: 10.3791/51107.

- e<sup>35</sup> Gehr S, Kaiser T, Kreutz R, et al. Suggestions for improving the design of clinical trials in multiple sclerosis-results of a systematic analysis of completed phase III trials. *EPMA J* 2019; 10: 425-436. 2019/12/14. DOI: 10.1007/s13167-019-00192-z.
- e<sup>36</sup> Chen TC, Cense B, Pierce MC, et al. Spectral domain optical coherence tomography: ultra-high speed, ultra-high resolution ophthalmic imaging. *Arch Ophthalmol* 2005; 123: 1715-1720. 2005/12/14. DOI: 10.1001/archophth.123.12.1715.
- e<sup>37</sup> Bock M, Brandt AU, Dorr J, et al. Time domain and spectral domain optical coherence tomography in multiple sclerosis: a comparative cross-sectional study. *Mult Scler* 2010; 16: 893-896. 2010/03/31. DOI: 10.1177/1352458510365156.
- e<sup>38</sup> Oertel FC, Havla J, Roca-Fernandez A, et al. Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. *J Neurol Neurosurg Psychiatry* 2018; 89: 1259-1265. 2018/06/21. DOI: 10.1136/jnnp-2018-318382.
- e<sup>39</sup> Oertel FC, Outteryck O, Knier B, et al. Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study. *J Neuroinflammation* 2019; 16: 154. 2019/07/28. DOI: 10.1186/s12974-019-1521-5.
- e<sup>40</sup> Motamedi S, Oertel FC, Yadav SK, et al. Altered fovea in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. *Neurol Neuroimmunol Neuroinflamm* 2020; 7 2020/06/25. DOI: 10.1212/NXI.0000000000000805.
- e<sup>41</sup> Filippatou AG, Vasileiou ES, He Y, et al. Evidence of subclinical quantitative retinal layer abnormalities in AQP4-IgG seropositive NMOSD. *Mult Scler* 2020; 1352458520977771. 2020/12/15. DOI: 10.1177/1352458520977771.
- e<sup>42</sup> Oertel FC, Kuchling J, Zimmermann H, et al. Microstructural visual system changes in AQP4-antibody-seropositive NMOSD. *Neurol Neuroimmunol Neuroinflamm* 2017; 4: e334. 2017/03/04. DOI: 10.1212/NXI.0000000000000334.
- e<sup>43</sup> Talman LS, Bisker ER, Sackel DJ, et al. Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. *Ann Neurol* 2010; 67: 749-760. 2010/06/03. DOI: 10.1002/ana.22005.
- e<sup>44</sup> Ratchford JN, Saidha S, Sotirchos ES, et al. Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. *Neurology* 2013; 80: 47-54. 2012/12/26. DOI: 10.1212/WNL.0b013e31827b1a1c.
- e<sup>45</sup> Caldito NG, Saidha S, Sotirchos ES, et al. Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study. *Brain* 2018; 141: 3115-3129. DOI: 10.1093/brain/awy245.
- e<sup>46</sup> Nolan-Kenney RC, Liu M, Akhand O, et al. Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study. *Ann Neurol* 2019; 85: 618-629. 2019/03/10. DOI: 10.1002/ana.25462.
- e<sup>47</sup> Waldman AT, Benson L, Sollee JR, et al. Interocular Difference in Retinal Nerve Fiber Layer Thickness Predicts Optic Neuritis in Pediatric-Onset Multiple Sclerosis. *J Neuroophthalmol* 2020 2020/10/27. DOI: 10.1097/WNO.0000000000001070.
- e<sup>48</sup> Narayan RN, McCreary M, Conger D, et al. Unique characteristics of optical coherence tomography (OCT) results and visual acuity testing in myelin oligodendrocyte glycoprotein (MOG) antibody positive pediatric patients. *Mult Scler Relat Disord* 2019; 28: 86-90. 2018/12/24. DOI: 10.1016/j.msard.2018.11.026.
- e<sup>49</sup> Kolbe S, Chapman C, Nguyen T, et al. Optic nerve diffusion changes and atrophy jointly predict visual dysfunction after optic neuritis. *Neuroimage* 2009; 45: 679-686. 2009/01/24. DOI: 10.1016/j.neuroimage.2008.12.047.

- e50 Chen JJ, Flanagan EP, Jitprapaikulsan J, López-Chiriboga ASS, Fryer JP, Leavitt JA, et al. Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. *Am J Ophthalmol*. 2018 Nov;195:8–15.
- e51 Akaishi T, Sato DK, Nakashima I, Takeshita T, Takahashi T, Doi H, et al. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study: Table 1. *J Neurol Neurosurg Psychiatry*. 2016 Apr;87(4):446–8.
- e52 Denève M, Biotti D, Patsoura S, Ferrier M, Meluchova Z, Mahieu L, et al. MRI features of demyelinating disease associated with anti-MOG antibodies in adults. *J Neuroradiol*. 2019 Sep 1;46(5):312–8.
- e53 Hickman SJ, Brierley CMH, Brex PA, et al. Continuing optic nerve atrophy following optic neuritis: a serial MRI study. *Multiple Sclerosis* 2002; 8: 339-342. DOI: papers3://publication/uuid/58A64527-5638-4D35-AC93-C2A9F267544B.
- e54 Naismith RT, Xu J, Tutlam NT, et al. Diffusion tensor imaging in acute optic neuropathies: predictor of clinical outcomes. *Arch Neurol* 2012; 69: 65-71. 2011/09/14. DOI: 10.1001/archneurol.2011.243.
- e55 Tian Y, Liu Z, Tang Z, et al. Radiomics Analysis of DTI Data to Assess Vision Outcome After Intravenous Methylprednisolone Therapy in Neuromyelitis Optic Neuritis. *J Magn Reson Imaging* 2019; 49: 1365-1373. 2018/09/27. DOI: 10.1002/jmri.26326.
- e56 Schmierer K, Scaravilli F, Altmann DR, et al. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. *Ann Neurol* 2004; 56: 407-415. 2004/09/07. DOI: 10.1002/ana.20202.
- e57 Mottershead JP, Schmierer K, Clemence M, et al. High field MRI correlates of myelin content and axonal density in multiple sclerosis--a post-mortem study of the spinal cord. *J Neurol* 2003; 250: 1293-1301. 2003/12/04. DOI: 10.1007/s00415-003-0192-3.
- e58 Melzi L, Rocca MA, Marzoli SB, et al. A longitudinal conventional and magnetization transfer magnetic resonance imaging study of optic neuritis. *Multiple Sclerosis* 2007; 13: 265-268. 10.1177/1352458506071212. DOI: papers3://publication/doi/10.1177/1352458506071212.
- e59 Klistorner A, Chaganti J, Garrick R, et al. Magnetisation transfer ratio in optic neuritis is associated with axonal loss, but not with demyelination. *Neuroimage* 2011; 56: 21-26. 2011/02/23. DOI: 10.1016/j.neuroimage.2011.02.041.
- e60 Wang Y, van der Walt A, Paine M, et al. Optic nerve magnetisation transfer ratio after acute optic neuritis predicts axonal and visual outcomes. *PLoS One* 2012; 7: e52291. 2012/12/29. DOI: 10.1371/journal.pone.0052291.
- e61 Oertel FC, Zimmermann HG, Brandt AU, et al. Novel uses of retinal imaging with optical coherence tomography in multiple sclerosis. *Expert Rev Neurother* 2019; 19: 31-43. 2018/12/28. DOI: 10.1080/14737175.2019.1559051.
- e62 Oertel FC, Zimmermann H, Paul F, et al. Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy. *EPMA J* 2018; 9: 21-33. 2018/03/09. DOI: 10.1007/s13167-017-0123-5.
- e63 Motamedi S, Gawlik K, Ayadi N, et al. Normative Data and Minimally Detectable Change for Inner Retinal Layer Thicknesses Using a Semi-automated OCT Image Segmentation Pipeline. *Front Neurol* 2019; 10: 1117. 2019/12/12. DOI: 10.3389/fneur.2019.01117.

- e64 Yadav SK, Motamedi S, Oberwahrenbrock T, et al. CuBe: parametric modeling of 3D foveal shape using cubic Bezier. *Biomed Opt Express* 2017; 8: 4181-4199. 2017/10/03. DOI: 10.1364/BOE.8.004181.
- e65 Yadav SK, Kadas EM, Motamedi S, et al. Optic nerve head three-dimensional shape analysis. *J Biomed Opt* 2018; 23: 1-13. 2018/10/14. DOI: 10.1117/1.JBO.23.10.106004.
- e66 Felix CM, Levin MH and Verkman AS. Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G. *J Neuroinflammation* 2016; 13: 275. 2016/10/22. DOI: 10.1186/s12974-016-0746-9.
- e67 Kwapong WR, Peng C, He Z, et al. Altered Macular Microvasculature in Neuromyelitis Optica Spectrum Disorders. *Am J Ophthalmol* 2018; 192: 47-55. 2018/05/12. DOI: 10.1016/j.ajo.2018.04.026.
- e68 Murphy OC, Kwakyi O, Iftikhar M, et al. Alterations in the retinal vasculature occur in multiple sclerosis and exhibit novel correlations with disability and visual function measures. *Mult Scler* 2020; 26: 815-828. 2019/05/17. DOI: 10.1177/1352458519845116.
- e69 Hadhoum N, Hodel J, Defoort-Dhellemmes S, et al. Length of optic nerve double inversion recovery hypersignal is associated with retinal axonal loss. *Mult Scler* 2016; 22: 649-658. 2015/08/01. DOI: 10.1177/1352458515598021.
- e70 Nolan R, Gelfand JM and Green AJ. Fingolimod treatment in multiple sclerosis leads to increased macular volume. *Neurology* 2013; 80: 139-144. DOI: 10.1212/WNL.0b013e31827b9132.
- e71 Al-Louzi O, Sotirchos ES, Vidal-Jordana A, et al. Characteristics of morphologic macular abnormalities in neuroimmunology practice. *Mult Scler* 2019; 25: 361-371. 2017/11/11. DOI: 10.1177/1352458517741206.
- e72 Kolbe SC, Marriott M, Walt A, et al. Diffusion tensor imaging correlates of visual impairment in multiple sclerosis and chronic optic neuritis. *Invest Ophthalmol Vis Sci* 2012; 53: 825-832. 2012/01/17. DOI: 10.1167/iovs.11-8864.
- e73 Van der Walt A, Butzkueven H, Kolbe S, et al. Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade. *Pharmacol Ther* 2010; 126: 82-93. 2010/02/04. DOI: 10.1016/j.pharmthera.2010.01.006.
- e74 Wieder L, Gade G, Pech LM, et al. Low contrast visual acuity testing is associated with cognitive performance in multiple sclerosis: a cross-sectional pilot study. *BMC Neurol* 2013; 13: 167. 2013/11/12. DOI: 10.1186/1471-2377-13-167.
- e75 Pineles SL, Birch EE, Talman LS, et al. One eye or two: a comparison of binocular and monocular low-contrast acuity testing in multiple sclerosis. *Am J Ophthalmol* 2011; 152: 133-140. 2011/05/17. DOI: 10.1016/j.ajo.2011.01.023.
- e76 Dorr J, Wernecke KD, Bock M, et al. Association of retinal and macular damage with brain atrophy in multiple sclerosis. *PLoS One* 2011; 6: e18132. 2011/04/16. DOI: 10.1371/journal.pone.0018132.
- e77 Young KL, Brandt AU, Petzold A, et al. Loss of retinal nerve fibre layer axons indicates white but not grey matter damage in early multiple sclerosis. *Eur J Neurol* 2013; 20: 803-811. 2013/02/02. DOI: 10.1111/ene.12070.
- e78 Saidha S, Sotirchos ES, Oh J, et al. Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis. *JAMA Neurol* 2013; 70: 34-43. 2013/01/16. DOI: 10.1001/jamaneurol.2013.573.

- e79 Zimmermann H, Freing A, Kaufhold F, et al. Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations. *Mult Scler* 2013; 19: 443-450. 2012/09/01. DOI: 10.1177/1352458512457844.
- e80 Klistorner A, Graham EC, Yiannikas C, et al. Progression of retinal ganglion cell loss in multiple sclerosis is associated with new lesions in the optic radiations. *Eur J Neurol* 2017; 24: 1392-1398. 2017/08/12. DOI: 10.1111/ene.13404.
- e81 Sinnecker T, Oberwahrenbrock T, Metz I, et al. Optic radiation damage in multiple sclerosis is associated with visual dysfunction and retinal thinning--an ultrahigh-field MR pilot study. *Eur Radiol* 2015; 25: 122-131. 2014/08/19. DOI: 10.1007/s00330-014-3358-8.
- e82 Backner Y, Ben-Shalom I, Kuchling J, et al. Cortical topological network changes following optic neuritis. *Neurol Neuroimmunol Neuroinflamm* 2020; 7 2020/03/04. DOI: 10.1212/NXI.0000000000000687.
- e83 Backner Y, Kuchling J, Massarwa S, et al. Anatomical Wiring and Functional Networking Changes in the Visual System Following Optic Neuritis. *JAMA Neurol* 2018; 75: 287-295. 2018/01/04. DOI: 10.1001/jamaneurol.2017.3880.
- e84 Finke C, Zimmermann H, Pache F, et al. Association of Visual Impairment in Neuromyelitis Optica Spectrum Disorder With Visual Network Reorganization. *JAMA Neurol* 2018; 75: 296-303. 2018/01/04. DOI: 10.1001/jamaneurol.2017.3890.
- e85 Coric D, Balk LJ, Verrijp M, et al. Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers. *Mult Scler* 2018; 24: 158-166. 2017/03/10. DOI: 10.1177/1352458517694090.
- e86 Birkeldh U, Manouchehrinia A, Hietala MA, et al. Retinal nerve fiber layer thickness associates with cognitive impairment and physical disability in multiple sclerosis. *Mult Scler Relat Disord* 2019; 36: 101414. 2019/10/02. DOI: 10.1016/j.msard.2019.101414.
- e87 Tavazzi E, Jakimovski D, Kuhle J, et al. Serum neurofilament light chain and optical coherence tomography measures in MS: A longitudinal study. *Neurol Neuroimmunol Neuroinflamm* 2020; 7 2020/05/20. DOI: 10.1212/NXI.0000000000000737.
- e88 Silbermann E, Wooliscroft L and Bourdette D. Using the Anterior Visual System to Assess Neuroprotection and Remyelination in Multiple Sclerosis Trials. *Current neurology and neuroscience reports* 2018; 18: 49. 10.1007/s11910-018-0858-y. DOI: papers3://publication/doi/10.1007/s11910-018-0858-y.
- e89 Zhang C, Zhang M, Qiu W, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. *Lancet Neurol* 2020; 19: 391-401. 2020/04/26. DOI: 10.1016/S1474-4422(20)30070-3.
- e90 Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER). 13/08/2015 ed.: ClinicalTrials.gov.
- e91 Cadavid D, Balcer L, Galetta S, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. *The Lancet Neurology* 2017; 16: 189-199. DOI: 10.1016/s1474-4422(16)30377-5.
- e92 Albert C, Mikolajczak J, Liekfeld A, et al. Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) - preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial. *BMC Neurol* 2020; 20: 75. 2020/03/05. DOI: 10.1186/s12883-020-01645-z.
- e93 Raftopoulos R, Hickman SJ, Toosy A, et al. Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. *The Lancet Neurology* 2016; 15: 259-269. DOI: 10.1016/s1474-4422(16)00004-1.

<sup>e94</sup> McKee JB, Cottrill CL, Elston J, et al. Amiloride does not protect retinal nerve fibre layer thickness in optic neuritis in a phase 2 randomised controlled trial. *Mult Scler* 2019; 25: 246-255. 2017/11/28. DOI: 10.1177/1352458517742979.